Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Among other criteria, patients must meet the following conditions to be eligible for the study:~1. Age ≥18 years of age.~2. Histologic diagnosis of glioblastoma (WHO Grade IV).~3. Documented EGFRvlll positive tumor status (central lab confirmation).~4. First or second relapse of de novo glioblastoma or first diagnosis or first relapse of secondary glioblastoma.~5. Previous treatment must include surgery, conventional radiation therapy and temozolomide (TMZ).~6. Screening MRI must be obtained at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy.~7. KPS of ≥ 70%.~8. If applicable, systemic corticosteroid therapy must be at a dose of ≤ 4 mg of dexamethasone or equivalent per day during the week prior to Day 1.~9. Evaluable disease in Groups 1 and 2; measurable disease in Group 2C~10. Life expectancy \> 12 weeks.~11. Patients in Group 2 and 2C must have had disease progression while receiving bevacizumab or within 2 months of treatment with bevacizumab.~Exclusion Criteria:~Among other criteria, patients who meet the following conditions are NOT eligible for the study:~1. Subjects unable to undergo an MRI with contrast.~2. History, presence, or suspicion of metastatic disease~3. Prior receipt of vaccination against EGFRvIII.~4. Any known contraindications to receipt of study drugs, including known allergy or hypersensitivity to keyhole limpet hemocyanin (KLH), GM-CSF (sargramostim; LEUKINE®), polysorbate 80 or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.~5. Use of non-protein based investigational therapy within 14 days prior to Day 1 or use of antibody-based investigational therapy within 28 days prior to Day 1.~6. Clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment~7. Evidence of recent hemorrhage on screening MRI of the brain~8. Evidence of current drug or alcohol abuse.~9. Patients in Group 1 must not have received prior treatment with bevacizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut. (Type: EXPERIMENTAL): About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
- Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control (Type: EXPERIMENTAL): About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
- Group 2 and 2C: Refractory to Bevacizumab (Type: EXPERIMENTAL): Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).

Based on this trial design, predict the completion outcome and termination type (if applicable).